Recent Finacing
Recent Raise
EIP Pharma is a clinical-stage CNS therapeutics company developing neflamapimod, an oral brain-penetrant p38α inhibitor in Phase 2 trials for early Alzheimer’s, dementia with Lewy bodies, and Huntington’s cognitive deficits.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
